Erratum to: Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)

被引：0
|
作者：
Hideki Kato
Masaomi Nangaku
Hideki Hirakata
Takashi Wada
Terumasa Hayashi
Hiroshi Sato
Yasushi Yamazaki
Takao Masaki
Tatsuo Kagimura
Hiroyasu Yamamoto
Hiroki Hase
Masahiro Kamouchi
Enyu Imai
Kyoichi Mizuno
Manabu Iwasaki
Tadao Akizawa
Yoshiharu Tsubakihara
Shoichi Maruyama
Ichiei Narita
机构：
[1] The University of Tokyo Graduate School of Medicine,Division of Nephrology and Endocrinology
[2] Fukuoka Renal Clinic,Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences
[3] Kanazawa University,Department of Kidney Disease and Hypertension
[4] Osaka General Medical Centre,Division of Clinical Pharmacology and Therapeutics
[5] Tohoku University Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences,Department of Nephrology and Rheumatology
[6] Kagawa Prefectural Central Hospital,Department of Nephrology
[7] Hiroshima University Hospital,Department of Internal Medicine
[8] Translational Research Informatics Center,Division of Nephrology
[9] Foundation Biomedical Research and Innovation,Department of Health Care Administration and Management, Graduate School of Medical Sciences
[10] Atsugi City Hospital,Nakayamadera Imai Clinic, Takarazuka, Hyogo, Department of Nephrology
[11] Toho University Ohashi Medical Center,Department of Computer and Information Science
[12] Kyushu University,Division of Nephrology, Department of Medicine
[13] Fujita Health University Toyoake,Course of Safety Management in Health Care Sciences, Graduate School of Health Care Sciences
[14] Mitsukoshi Health and Welfare Foundation,Department of Nephrology
[15] Seikei University,Division of Clinical Nephrology and Rheumatology
[16] Showa University School of Medicine,undefined
[17] Jikei Institute,undefined
[18] Nagoya University Graduate School of Medicine,undefined
[19] Niigata University Graduate School of Medical and Dental Sciences,undefined
来源：
Clinical and Experimental Nephrology | 2018年 / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：85 / 86
页数：1
相关论文
共 50 条
  • [1] Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
    Kato, Hideki
    Nangaku, Masaomi
    Hirakata, Hideki
    Wada, Takashi
    Hayashi, Terumasa
    Sato, Hiroshi
    Yamazaki, Yasushi
    Masaki, Takao
    Kagimura, Tatsuo
    Yamamoto, Hiroyasu
    Hase, Hiroki
    Kamouchi, Masahiro
    Imai, Enyu
    Mizuno, Kyoichi
    Iwasaki, Manabu
    Akizawa, Tadao
    Tsubakihara, Yoshiharu
    Maruyama, Shoichi
    Narita, Ichiei
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2018, 22 (01) : 78 - 84
  • [2] Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naive to erythropoiesis-stimulating agents
    Silver, M. R.
    Geronemus, R.
    Krause, M.
    Chen, C. Y.
    Kewalramani, R.
    Stehman-Breen, C.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (01) : 123 - 131
  • [3] Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
    Kim, Sun Moon
    Kim, Kyeong Min
    Kwon, Soon Kil
    Kim, Hye-Young
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2016, 31 (01) : 55 - 60
  • [4] Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease
    Kuwahara, Michio
    Mandai, Shintaro
    Kasagi, Yuri
    Kusaka, Keita
    Tanaka, Tomomi
    Shikuma, Satomi
    Akita, Wataru
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2015, 19 (04) : 598 - 605
  • [5] Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease
    Michio Kuwahara
    Shintaro Mandai
    Yuri Kasagi
    Keita Kusaka
    Tomomi Tanaka
    Satomi Shikuma
    Wataru Akita
    Clinical and Experimental Nephrology, 2015, 19 : 598 - 605
  • [6] Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients
    Kuwahara, Michio
    Hasumi, Syoko
    Mandai, Shintaro
    Tanaka, Tomomi
    Shikuma, Satomi
    Akita, Wataru
    Mori, Yoshihiro
    Sasaki, Sei
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (05) : 755 - 762
  • [7] Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients
    Michio Kuwahara
    Syoko Hasumi
    Shintaro Mandai
    Tomomi Tanaka
    Satomi Shikuma
    Wataru Akita
    Yoshihiro Mori
    Sei Sasaki
    Clinical and Experimental Nephrology, 2014, 18 : 755 - 762
  • [8] Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia
    Maruyama, Takashi
    Higuchi, Terumi
    Yamazaki, Toshio
    Okawa, Erina
    Ando, Hideyuki
    Oikawa, Osamu
    Inoshita, Atsushi
    Okada, Kazuyoshi
    Abe, Masanori
    CARDIORENAL MEDICINE, 2017, 7 (03) : 188 - 197
  • [9] Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease
    Del Vecchio, Lucia
    Locatelli, Francesco
    EXPERT OPINION ON DRUG SAFETY, 2012, 11 (06) : 923 - 931
  • [10] Is it safe to use erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients with active malignancies?
    Gupta, Gaurav
    Choi, Michael J.
    SEMINARS IN DIALYSIS, 2011, 24 (04) : 379 - 381
12345